Trial Outcomes & Findings for Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) (NCT NCT03326986)
NCT ID: NCT03326986
Last Updated: 2020-01-09
Results Overview
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
24 participants
Primary outcome timeframe
Up to approximately 21 weeks
Results posted on
2020-01-09
Participant Flow
Participants in Panels A and B received a single-rising dose of MK-7252 or placebo in 5 alternating dosing periods. Participants in Panel C received a single-rising dose of MK-7252 or placebo in 3/5 planned periods (P). A 180 mg dose was added (P3). P4-5 were not run so the 240, 360, 540, and 120 mg fed and placebo fed doses were not given.
Participant milestones
| Measure |
Panel A
Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (1 mg, 6 mg, 24 mg, 72 mg, or 108 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel B.
|
Panel B
Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (3 mg, 12 mg, 48 mg, 72 mg, or 162 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel A.
|
Panel C
Within each of 3 single dose treatment periods, 6 participants received a single dose of MK-7252 (120 mg or 180 mg) and 2 participants received placebo in a fasted state. The 120 mg dose of MK-7252 was administered in the first 2 periods and the 180 mg dose was administered in the third period.
|
|---|---|---|---|
|
Overall Study
STARTED
|
8
|
8
|
8
|
|
Overall Study
COMPLETED
|
8
|
8
|
8
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
Baseline characteristics by cohort
| Measure |
Panel A
n=8 Participants
Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (1 mg, 6 mg, 24 mg, 72 mg, or 108 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel B.
|
Panel B
n=8 Participants
Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (3 mg, 12 mg, 48 mg, 72 mg, or 162 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel A.
|
Panel C
n=8 Participants
Within each of 3 single dose treatment periods, 6 participants received a single dose of MK-7252 (120 mg or 180 mg) and 2 participants received placebo in a fasted state. The 120 mg dose of MK-7252 was administered in the first 2 periods and the 180 mg dose was administered in the third period.
|
Total
n=24 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
8 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
24 Participants
n=157 Participants
|
|
Age, Continuous
|
33.0 Years
STANDARD_DEVIATION 10.2 • n=99 Participants
|
35.0 Years
STANDARD_DEVIATION 9.5 • n=107 Participants
|
34.4 Years
STANDARD_DEVIATION 9.3 • n=206 Participants
|
34.1 Years
STANDARD_DEVIATION 9.3 • n=157 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
3 Participants
n=157 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
21 Participants
n=157 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
White
|
8 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
24 Participants
n=157 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=157 Participants
|
PRIMARY outcome
Timeframe: Up to approximately 21 weeksPopulation: All participants who received at least 1 dose of study treatment and experienced an AE during the study period
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=12 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=8 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=22 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants Who Experienced at Least One Adverse Event (AE)
|
2 Participants
|
5 Participants
|
4 Participants
|
5 Participants
|
5 Participants
|
4 Participants
|
7 Participants
|
5 Participants
|
6 Participants
|
4 Participants
|
2 Participants
|
15 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to approximately 19 weeksPopulation: All participants who received at least 1 dose of study treatment and discontinued during the study period
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=12 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=8 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=22 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants Who Discontinued Study Treatment Due to an AE
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1) and 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4-5 of Panel C were not conducted; the planned 120 mg fed dose (P 5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=5 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=5 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)
|
NA hr•nmol/L
Geometric mean and 95% confidence interval were not calculated for the 1 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the AUC0-∞ at this dose level.
|
NA hr•nmol/L
Geometric mean and 95% confidence interval were not calculated for the 3 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the AUC0-∞ at this dose level.
|
288 hr•nmol/L
Interval 195.0 to 427.0
|
583 hr•nmol/L
Interval 394.0 to 862.0
|
1190 hr•nmol/L
Interval 805.0 to 1750.0
|
2040 hr•nmol/L
Interval 1390.0 to 3000.0
|
5090 hr•nmol/L
Interval 3460.0 to 7490.0
|
3500 hr•nmol/L
Interval 2380.0 to 5160.0
|
6680 hr•nmol/L
Interval 4530.0 to 9840.0
|
9840 hr•nmol/L
Interval 6690.0 to 14500.0
|
7260 hr•nmol/L
Interval 4930.0 to 10700.0
|
5520 hr•nmol/L
Interval 3720.0 to 8170.0
|
10300 hr•nmol/L
Interval 6970.0 to 15300.0
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, and 24 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)
|
47.8 hr•nmol/L
Interval 32.4 to 70.4
|
122 hr•nmol/L
Interval 82.4 to 179.0
|
279 hr•nmol/L
Interval 189.0 to 411.0
|
559 hr•nmol/L
Interval 379.0 to 824.0
|
1150 hr•nmol/L
Interval 781.0 to 1700.0
|
2030 hr•nmol/L
Interval 1380.0 to 3000.0
|
5210 hr•nmol/L
Interval 3530.0 to 7680.0
|
3490 hr•nmol/L
Interval 2370.0 to 5150.0
|
6420 hr•nmol/L
Interval 4350.0 to 9470.0
|
9530 hr•nmol/L
Interval 6460.0 to 14100.0
|
7240 hr•nmol/L
Interval 4900.0 to 10700.0
|
5510 hr•nmol/L
Interval 3710.0 to 8200.0
|
10300 hr•nmol/L
Interval 6910.0 to 15300.0
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, and 12 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)
|
47.8 hr•nmol/L
Interval 32.5 to 70.4
|
121 hr•nmol/L
Interval 82.5 to 179.0
|
278 hr•nmol/L
Interval 189.0 to 409.0
|
558 hr•nmol/L
Interval 379.0 to 822.0
|
1140 hr•nmol/L
Interval 775.0 to 1680.0
|
2020 hr•nmol/L
Interval 1370.0 to 2980.0
|
5130 hr•nmol/L
Interval 3480.0 to 7540.0
|
3450 hr•nmol/L
Interval 2340.0 to 5070.0
|
6220 hr•nmol/L
Interval 4220.0 to 9160.0
|
9240 hr•nmol/L
Interval 6270.0 to 13600.0
|
7170 hr•nmol/L
Interval 4860.0 to 10600.0
|
5480 hr•nmol/L
Interval 3690.0 to 8130.0
|
10200 hr•nmol/L
Interval 6840.0 to 15100.0
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)
|
38.7 hr•nmol/L
Interval 26.0 to 57.6
|
101 hr•nmol/L
Interval 68.1 to 151.0
|
250 hr•nmol/L
Interval 168.0 to 371.0
|
543 hr•nmol/L
Interval 365.0 to 808.0
|
1130 hr•nmol/L
Interval 757.0 to 1680.0
|
2030 hr•nmol/L
Interval 1360.0 to 3020.0
|
5170 hr•nmol/L
Interval 3470.0 to 7690.0
|
3420 hr•nmol/L
Interval 2300.0 to 5090.0
|
6330 hr•nmol/L
Interval 4250.0 to 9420.0
|
9750 hr•nmol/L
Interval 6550.0 to 14500.0
|
7250 hr•nmol/L
Interval 4860.0 to 10800.0
|
5500 hr•nmol/L
Interval 3670.0 to 8260.0
|
10300 hr•nmol/L
Interval 6860.0 to 15500.0
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Maximal Plasma Concentration (Cmax)
|
21.2 nmol/L
Interval 15.4 to 29.4
|
51.7 nmol/L
Interval 37.4 to 71.5
|
117 nmol/L
Interval 84.6 to 162.0
|
220 nmol/L
Interval 159.0 to 305.0
|
447 nmol/L
Interval 323.0 to 618.0
|
830 nmol/L
Interval 600.0 to 1150.0
|
1860 nmol/L
Interval 1340.0 to 2570.0
|
1380 nmol/L
Interval 997.0 to 1910.0
|
2290 nmol/L
Interval 1660.0 to 3170.0
|
3380 nmol/L
Interval 2440.0 to 4670.0
|
3160 nmol/L
Interval 2280.0 to 4380.0
|
2550 nmol/L
Interval 1820.0 to 3580.0
|
3880 nmol/L
Interval 2760.0 to 5440.0
|
—
|
SECONDARY outcome
Timeframe: 12 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 1 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 3 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 6 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 12 mg dose level being below the LLOQ (2.74 nmol/L).
|
2.19 nmol/L
Interval 1.17 to 4.1
|
2.95 nmol/L
Interval 1.57 to 5.51
|
11.7 nmol/L
Interval 6.29 to 21.7
|
7.06 nmol/L
Interval 3.8 to 13.1
|
21.0 nmol/L
Interval 11.2 to 39.2
|
31.8 nmol/L
Interval 17.0 to 59.6
|
10.4 nmol/L
Interval 5.59 to 19.3
|
7.16 nmol/L
Interval 3.76 to 13.7
|
16.7 nmol/L
Interval 8.77 to 31.9
|
—
|
SECONDARY outcome
Timeframe: 24 hours postdosePopulation: All participants who received study treatment, complied with the protocol to ensure data were likely to exhibit effects of treatment according to the scientific model, and had data available for endpoint. Periods 4-5 of Panel C was not conducted and planned 120 mg fed dose not administered. Analysis was not performed due to values being \<LLOQ.
Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 1 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 3 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 6 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 12 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 24 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 48 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 72 mg dose in level in Panel A being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 72 mg dose level in Panel B being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 108 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 162 mg dose level being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 120 mg dose level in Panel C Period 1 being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 120 mg dose level in Panel C Period 2 being below the LLOQ (2.74 nmol/L).
|
NA nmol/L
Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 180 mg dose level in Panel C Period 3 being below the LLOQ (2.74 nmol/L).
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Time to Reach Maximal Concentration (Tmax)
|
1.00 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
1.00 hr
Interval 0.5 to 1.0
|
1.00 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
1.00 hr
Interval 0.5 to 2.0
|
1.00 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
0.75 hr
Interval 0.5 to 1.0
|
1.00 hr
Interval 0.5 to 1.0
|
1.00 hr
Interval 0.5 to 1.0
|
—
|
SECONDARY outcome
Timeframe: Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdosePopulation: All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.
Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=5 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=5 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MK-7252 Apparent Terminal Half-life (t½)
|
NA hr
Geometric Coefficient of Variation NA
Geometric mean and 95% confidence interval were not calculated for the 1 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the t½ at this dose level.
|
NA hr
Geometric Coefficient of Variation NA
Geometric mean and 95% confidence interval were not calculated for the 3 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the t½ at this dose level.
|
1.29 hr
Geometric Coefficient of Variation 12.18
|
1.34 hr
Geometric Coefficient of Variation 14.99
|
1.60 hr
Geometric Coefficient of Variation 19.86
|
1.35 hr
Geometric Coefficient of Variation 9.93
|
1.76 hr
Geometric Coefficient of Variation 60.34
|
1.59 hr
Geometric Coefficient of Variation 19.54
|
3.09 hr
Geometric Coefficient of Variation 81.14
|
5.97 hr
Geometric Coefficient of Variation 92.18
|
1.96 hr
Geometric Coefficient of Variation 52.80
|
2.40 hr
Geometric Coefficient of Variation 71.03
|
2.90 hr
Geometric Coefficient of Variation 152.97
|
—
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 4 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 4 hours postdose
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Measurement sets
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Measurement sets
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Measurement sets
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Measurement sets
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Measurement sets
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Measurement sets
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Measurement sets
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Measurement sets
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Measurement sets
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Measurement sets
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Measurement sets
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Measurement sets
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=25 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours
|
5.61 mmHg
Standard Error 1.94
|
1.56 mmHg
Standard Error 2.57
|
0.50 mmHg
Standard Error 2.66
|
4.39 mmHg
Standard Error 2.08
|
6.78 mmHg
Standard Error 3.71
|
12.17 mmHg
Standard Error 1.57
|
14.00 mmHg
Standard Error 4.28
|
9.83 mmHg
Standard Error 0.84
|
11.28 mmHg
Standard Error 1.90
|
5.33 mmHg
Standard Error 2.15
|
18.17 mmHg
Standard Error 7.65
|
3.80 mmHg
Standard Error 4.15
|
6.13 mmHg
Standard Error 4.52
|
3.22 mmHg
Standard Error 1.84
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 24 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 24 hours postdose
Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Measurement sets
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Measurement sets
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Measurement sets
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Measurement sets
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Measurement sets
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Measurement sets
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Measurement sets
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Measurement sets
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Measurement sets
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Measurement sets
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Measurement sets
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Measurement sets
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=25 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours
|
2.83 mmHg
Standard Error 3.40
|
0.89 mmHg
Standard Error 3.00
|
-1.11 mmHg
Standard Error 1.56
|
-3.56 mmHg
Standard Error 2.47
|
-0.17 mmHg
Standard Error 2.75
|
-0.56 mmHg
Standard Error 2.48
|
7.56 mmHg
Standard Error 1.32
|
3.56 mmHg
Standard Error 1.81
|
0.22 mmHg
Standard Error 3.36
|
3.17 mmHg
Standard Error 1.61
|
4.67 mmHg
Standard Error 3.51
|
-0.13 mmHg
Standard Error 4.98
|
7.27 mmHg
Standard Error 3.86
|
5.84 mmHg
Standard Error 1.48
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 4 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 4 hours postdose
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Measurement sets
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Measurement sets
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Measurement sets
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Measurement sets
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Measurement sets
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Measurement sets
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Measurement sets
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=22 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours
|
1.11 mmHg
Standard Error 1.77
|
1.61 mmHg
Standard Error 1.06
|
0.33 mmHg
Standard Error 1.88
|
2.28 mmHg
Standard Error 3.24
|
6.33 mmHg
Standard Error 1.55
|
6.22 mmHg
Standard Error 1.56
|
5.50 mmHg
Standard Error 2.03
|
7.28 mmHg
Standard Error 2.24
|
4.61 mmHg
Standard Error 1.24
|
5.33 mmHg
Standard Error 1.43
|
5.28 mmHg
Standard Error 1.24
|
11.27 mmHg
Standard Error 3.12
|
5.67 mmHg
Standard Error 1.96
|
0.61 mmHg
Standard Error 0.83
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 24 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 24 hours postdose
Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Measurement sets
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Measurement sets
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Measurement sets
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Measurement sets
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Measurement sets
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Measurement sets
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Measurement sets
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Measurement sets
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Measurement sets
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Measurement sets
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Measurement sets
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Measurement sets
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=25 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours
|
0.61 mmHg
Standard Error 1.31
|
2.78 mmHg
Standard Error 3.13
|
-2.67 mmHg
Standard Error 2.86
|
-3.33 mmHg
Standard Error 2.23
|
2.33 mmHg
Standard Error 1.69
|
-1.11 mmHg
Standard Error 2.03
|
2.11 mmHg
Standard Error 1.91
|
1.72 mmHg
Standard Error 1.62
|
-0.78 mmHg
Standard Error 2.49
|
4.11 mmHg
Standard Error 1.89
|
1.28 mmHg
Standard Error 1.59
|
4.00 mmHg
Standard Error 1.15
|
4.73 mmHg
Standard Error 1.16
|
1.99 mmHg
Standard Error 0.83
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 4 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 4 hours postdose
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Participants
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Participants
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Participants
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Participants
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Participants
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Participants
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Participants
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Participants
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Participants
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Participants
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Participants
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Participants
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=22 Participants
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Heart Rate (HR) at 4 Hours
|
-4.22 beats per minute
Standard Error 1.82
|
-0.28 beats per minute
Standard Error 2.66
|
-1.22 beats per minute
Standard Error 1.68
|
-0.89 beats per minute
Standard Error 1.76
|
0.22 beats per minute
Standard Error 0.88
|
0.17 beats per minute
Standard Error 1.72
|
6.83 beats per minute
Standard Error 7.05
|
2.28 beats per minute
Standard Error 2.99
|
0.83 beats per minute
Standard Error 2.21
|
1.33 beats per minute
Standard Error 2.10
|
2.17 beats per minute
Standard Error 6.07
|
-1.53 beats per minute
Standard Error 1.36
|
1.27 beats per minute
Standard Error 2.15
|
-1.27 beats per minute
Standard Error 0.91
|
SECONDARY outcome
Timeframe: Baseline (Predose Day 1) and 24 hours postdosePopulation: All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 24 hours postdose
Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.
Outcome measures
| Measure |
MK-7252 1 mg
n=6 Measurement sets
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 Measurement sets
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 Measurement sets
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 Measurement sets
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 Measurement sets
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 Measurement sets
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=6 Measurement sets
Single oral dose of 72 mg MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 Measurement sets
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=6 Measurement sets
Single oral dose of 120 mg MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 Measurement sets
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=6 Measurement sets
Single oral dose of 180 mg MK-7252 administered in a fasted state
|
Placebo
n=5 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Panel C MK-7252 180 mg Period 3
n=5 Measurement sets
Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state
|
Placebo
n=25 Measurement sets
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Heart Rate (HR) at 24 Hours
|
-2.78 beats per minute
Standard Error 2.01
|
2.72 beats per minute
Standard Error 2.03
|
1.83 beats per minute
Standard Error 1.38
|
3.89 beats per minute
Standard Error 1.55
|
2.89 beats per minute
Standard Error 1.19
|
1.67 beats per minute
Standard Error 1.41
|
2.94 beats per minute
Standard Error 1.73
|
2.17 beats per minute
Standard Error 2.15
|
-0.61 beats per minute
Standard Error 1.46
|
2.67 beats per minute
Standard Error 2.18
|
-0.72 beats per minute
Standard Error 2.53
|
1.40 beats per minute
Standard Error 1.26
|
2.33 beats per minute
Standard Error 1.13
|
2.23 beats per minute
Standard Error 1.27
|
Adverse Events
MK-7252 1 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
MK-7252 3 mg
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
MK-7252 6 mg
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
MK-7252 12 mg
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
MK-7252 24 mg
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
MK-7252 48 mg
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
MK-7252 72 mg
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
MK-7252 108 mg
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
MK-7252 120 mg
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
MK-7252 162 mg
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
MK-7252 180 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 15 other events
Deaths: 0 deaths
Post-Study
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
MK-7252 1 mg
n=6 participants at risk
Single oral dose of 1 mg MK-7252 administered in a fasted state
|
MK-7252 3 mg
n=6 participants at risk
Single oral dose of 3 mg MK-7252 administered in a fasted state
|
MK-7252 6 mg
n=6 participants at risk
Single oral dose of 6 mg MK-7252 administered in a fasted state
|
MK-7252 12 mg
n=6 participants at risk
Single oral dose of 12 mg MK-7252 administered in a fasted state
|
MK-7252 24 mg
n=6 participants at risk
Single oral dose of 24 mg MK-7252 administered in a fasted state
|
MK-7252 48 mg
n=6 participants at risk
Single oral dose of 48 mg MK-7252 administered in a fasted state
|
MK-7252 72 mg
n=12 participants at risk
Single oral dose of 72 mg of MK-7252 administered in a fasted state
|
MK-7252 108 mg
n=6 participants at risk
Single oral dose of 108 mg MK-7252 administered in a fasted state
|
MK-7252 120 mg
n=8 participants at risk
Single oral dose of 120 mg of MK-7252 administered in a fasted state
|
MK-7252 162 mg
n=6 participants at risk
Single oral dose of 162 mg MK-7252 administered in a fasted state
|
MK-7252 180 mg
n=5 participants at risk
Single oral dose of 180 mg of MK-7252 administered in a fasted state
|
Placebo
n=22 participants at risk
Single oral dose of placebo to match MK-7252 administered in a fasted state
|
Post-Study
n=24 participants at risk
MK-7252 or placebo as a single dose in the post-study period administered in a fasted state
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Vascular disorders
Peripheral coldness
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Vascular disorders
Hypertension
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
2/12 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Cardiac disorders
Postural orthostatic tachycardia syndrome
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Ear and labyrinth disorders
Cerumen impaction
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Eye disorders
Eye irritation
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Eye disorders
Photophobia
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Abdominal discomfort
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
20.0%
1/5 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
20.0%
1/5 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Diarrhoea
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
25.0%
2/8 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
20.0%
1/5 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Mouth swelling
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 3 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
9.1%
2/22 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Catheter site haematoma
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Catheter site pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Chest discomfort
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Fatigue
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Feeling of body temperature change
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
General disorders
Mucosal pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Angular cheilitis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.2%
1/24 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Cystitis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
2/24 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Oral herpes
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Pyuria
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.2%
1/24 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Sinusitis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Infections and infestations
Vulvovaginitis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Injury, poisoning and procedural complications
Muscle contusion
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Investigations
Orthostatic heart rate response increased
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
9.1%
2/22 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
2/12 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Muscle twitching
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
2/12 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.2%
1/24 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Myofascial pain syndrome
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
—
0/0 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Musculoskeletal and connective tissue disorders
Trismus
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Dizziness
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
9.1%
2/22 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Headache
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
50.0%
3/6 • Number of events 3 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 3 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
36.4%
8/22 • Number of events 8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.2%
1/24 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Sensory loss
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Nervous system disorders
Visual field defect
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Psychiatric disorders
Irritability
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
12.5%
1/8 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
33.3%
2/6 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Respiratory, thoracic and mediastinal disorders
Throat tightness
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Skin and subcutaneous tissue disorders
Cold sweat
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
50.0%
3/6 • Number of events 3 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
9.1%
2/22 • Number of events 2 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
8.3%
1/12 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
16.7%
1/6 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/22 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/12 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/8 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/6 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/5 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
4.5%
1/22 • Number of events 1 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
0.00%
0/24 • Up to approximately 21 weeks
The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.
- Publication restrictions are in place
Restriction type: OTHER